Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Te

Fresenius Medical Care Announces the Offering of

250 million of Senior Notes for Refinancing Purposes

Bad Homburg, Germany

Fresenius Medical Care AG & Co. KGaA (the Company or Fresenius Medical

Care ), the world s largest provider of dialysis products and services, today

announced that it intends to sell 250 million of senior unsecured notes due

2016 (the Senior Notes ) issued by FMC Finance VI S.A., a wholly owned

subsidiary of the Company. The Senior Notes will be offered through a private

placement directed to institutional investors outside the United States. There

will be no public offering of the Senior Notes. Proceeds from the offering will

be used to repay short-term indebtedness and for general corporate purposes.

Notes will be guaranteed on a senior basis jointly and severally by the

Company, Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care

offering will not be registered under the Securities Act of 1933. The offering

will be made in an offshore transaction pursuant to Regulation S under the

Securities Act and will be offered in the United States to qualified

institutional buyers pursuant to the exemption from registration under Rule

144A under the Securities Act.

This release does not

constitute or form part of, and should not be construed as, an offer or

invitation to subscribe for, underwrite or otherwise acquire, any securities of

FMC Finance VI S.A. or Fresenius Medical Care or any present or future member

of its group nor should it or any part of it form the basis of, or be relied on

in connection with, any contract to purchase or subscribe for any securities of

FMC Finance VI S.A. or Fresenius Medical Care or any member of its group. In

particular, this release is not an offer of securities in the United States of America

(including its territories and possessions), and securities of FMC Finance VI

S.A. and Fresenius Medical Care may not be offered or sold in the United States

of America absent registration under the Securities Act of 1933, as amended,

(which FMC Finance VI S.A. and Fresenius Medical Care do not intend to effect)

or pursuant to an applicable exemption from registration.

Fresenius Medical Care is the

world's largest integrated provider of products and services for individuals

undergoing dialysis because of chronic kidney failure, a condition that affects

more than 1,770,000 individuals worldwide. Through its network of 2,509

dialysis clinics in North America, Europe, Latin America, Asia-Pacific and

Africa, Fresenius Medical Care provides dialysis treatment to 192,804 patients

around the globe (as of 30 September 2009). Fresenius Medical Care is also the

world's leading provider of dialysis products such as hemodialysis machines,

dialyzers and related disposable products. Fresenius Medical Care is listed on

the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS,

FMS/P). For more information about Fresenius Medical Care, visit the Company s

website at www.fmc-ag.com.

This release contains

forward-looking statements that are subject to various risks and uncertainties.

Actual results could differ materially from those described in these

forward-looking statements due to certain factors, including changes in

business, economic and competitive conditions, regulatory reforms, foreign exchange

rate fluctuations, uncertainties in litigation or investigative proceedings,

and the availability of financing. These and other risks and uncertainties are

detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the

U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.

KGaA does not undertake any responsibility to update the forward-looking

statements in this release.